AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03052374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VID-KIDS Intervention Program
Description: Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol.
Study NCT03330977 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compression garments
Description: Patients will wear the compression garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the compression garments at inclusion.
Study NCT01904084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volar locked plating
Description: Operative treatment of distal radius fracture with volar locking plate
Study NCT01904084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hoffman external fixator
Description: Patients with distal radius fracture operated with Hoffman external fixator
Study NCT03267316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN04
Description: A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
Study NCT03267316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard of care treatment
Study NCT03267316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care treatment
Study NCT03267316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Standard of care treatment
Study NCT03267316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care treatment
Study NCT03267316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Standard of care treatment
Study NCT02709759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational intervention
Description: Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
Study NCT02709759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Involves 5-10 minutes of brief counseling to reduce drinking
Study NCT02709759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive text messaging
Description: Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
Study NCT03926728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTH522-CAF01 IM
Description: On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
Study NCT03926728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTH522-CAF09b IM
Description: On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
Study NCT03926728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTH522 ID
Description: 24 mcg CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 mL syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
Study NCT03926728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTH522 TO
Description: 24 mcg CTH522 (12 mcg in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
Study NCT03926728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Saline)
Description: Placebo only given as IM, ID and TO.
Study NCT03926728 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Placebo only given as IM, ID and TO.
Study NCT03486327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: A novel targeted ultrasound contrast agent
Study NCT01578018 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measure DCAM levels in blood
Description: Measure DCAM levels in blood
Study NCT01578018 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DCAM levels in blood
Description: DCAM levels in blood
Study NCT03159000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1ml of 1/3 saline
Study NCT03159000 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: lidocaine/bupivacaine
Description: 1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine
Study NCT01009073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed.
Study NCT01009073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg of erlotinib is taken orally once daily.
Study NCT01009073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan (3-week schedule)
Description: 180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed.
Study NCT01009073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan (weekly schedule)
Description: 75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed.
Study NCT02737072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Administered SQ
Study NCT02737072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered IV
Study NCT02816658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Inguinal Hernia Repair
Description: Laparoscopic Inguinal Hernia Repair
Study NCT02816658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Inguinal Hernia Repair
Description: Robotic Inguinal Hernia Repair
Study NCT04642131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Description: Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.
Study NCT04642131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized insoles
Description: Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine
Study NCT04642131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control condition
Description: Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
Study NCT01534429 — intervention group
Intervention type: PROCEDURE
Intervention: Quantitative Sensory Testing
Description: Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
Study NCT02981667 — intervention group
Intervention type: OTHER
Intervention: Exercise intensity
Description: Participants were randomized to 1 or 2 exercise intensities, moderate or high (interval training).
Study NCT00296192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine nasal spray
Description: Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
Study NCT00296192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo nasal spray 1, 2 3, and 4 puffs
Study NCT01875419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between.
Study NCT01281488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Given IV
Study NCT01875419 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: 8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
Study NCT01875419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: 8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
Study NCT00877799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
Study NCT00877799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
Study NCT00877799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
Study NCT00877799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo administered the day after surgery (Day 1)
Study NCT00877799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo administered immediately after surgery (Day 0)
Study NCT01981434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video game based obesity education
Description: The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
Study NCT00739206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR97276A
Description: Dose based on body weight
Study NCT01711034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles.
Study NCT01158924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradiscal rhGDF-5
Description: The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
Study NCT04613609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarette containing nicotine
Description: Non-smokers used an electronic cigarette containing nicotine
Study NCT04613609 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electronic Cigarette without nicotine
Description: Non-smokers used an electronic cigarette without nicotine
Study NCT01014507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8 cycles BEACOPPesc plus oral contraceptive
Study NCT01014507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 cycles BEACOPPesc plus Goserelin
Study NCT02857127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking program
Description: To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
Study NCT00562874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat Biscuit
Description: 75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
Study NCT00562874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Biscuit
Description: 75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
Study NCT00784446 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Oxaliplatin, Capecitabine, Bevacizumab, Imatinib
Description: Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.
Study NCT00902356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 167
Description: Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
Study NCT00902356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
Study NCT00934271 — intervention group
Intervention type: RADIATION
Intervention: fractionated stereotactic radiotherapy
Description: Audit of outcome
Study NCT00724451 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b
Description: Peginterferon alfa-2b administered in accordance with approved labeling
Study NCT00724451 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin administered in accordance with approved labeling
Study NCT00724451 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a administered in accordance with approved labeling
Study NCT00562874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Wheat Biscuit
Description: 75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
Study NCT01632800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High pulsed magnetic fields
Description: Magnetic fields will escalate in strength
Study NCT05337878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pelacarsen-matching placebo administered by SC injection.
Study NCT00136565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: 1.5 mg/m², D1, D5, 4 cycles
Study NCT05337878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Description: Pelacarsen administered by SC injection.
Study NCT00136565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m², D1, 4 cycles
Study NCT00136565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m², D1-D5, 4 cycles
Study NCT00136565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1200 mg/m², D1, 4 cycles
Study NCT00136565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: 2 mg/m², D1, D5, 4 cycles
Study NCT02651623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Multiple doses of sertraline for 14 days
Study NCT02651623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: A single dose of 400 mg Moxifloxacin
Study NCT02651623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug - Placebo
Description: Placebo administered for 14 days
Study NCT03992690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol
Description: Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
Study NCT03992690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Training with traditional physiotherapy protocol
Description: Stretching
Study NCT01470287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib Vaccine
Description: Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
Study NCT00136565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 mg, D1, D5, 4 cycles
Study NCT04496765 — intervention group
Intervention type: PROCEDURE
Intervention: Total mesorectal excision
Description: Radical resection of rectal cancer and draining lymph nodes
Study NCT01734226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prunus Mume Extract
Description: Prunus Mume Extract (3.94g/day)
Study NCT01734226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3.94g/day)
Study NCT01131481 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular lens
Study NCT03799458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active High-definition transcranial direct current stimulation (HD-tDCS)
Description: Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
Study NCT03073291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsible Marijuana Vendor Training
Description: Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
Study NCT01394120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Therapy Tailored Treatment
Description: Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib
Study NCT03799458 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High-definition transcranial direct current stimulation (HD-tDCS)
Description: Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates